       |
Investors
Epitarget AS is a privately owned Scandinavian life science company headquartered in Oslo, Norway. The company is dedicated to developing novel cancer therapies. In current chemotherapy the whole body is treated, not only the diseased parts, severely limiting therapy. Epitarget aims to change this by delivering effective cancer drugs exactly where they are needed.
Revenues will be generated from licensing deals not later than clinical phase II within a USD 45 bill. cancer drug market. The technology can be extended to any condition where local drug delivery is beneficial, like cardiovascular, neurological, and inflammatory diseases. 15 Largest Shareholders (Updated 25 June 2010)
|
|||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||
